The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Open accessAbstract
Recurrent mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 have been identified in gliomas, acute myeloid leukaemias (AML) and chondrosarcomas, and share a novel enzymatic property of producing 2-hydroxyglutarate (2HG) from α-ketoglutarate. Here we report that 2HG-producing IDH mutants can prevent the histone demethylation that is required for lineage-specific progenitor cells to differentiate into terminally differentiated cells. In tumour samples from glioma patients, IDH mutations were associated with a distinct gene expression profile enriched for genes expressed in neural progenitor cells, and this was associated with increased histone methylation. To test whether the ability of IDH mutants to promote histone methylation contributes to a block in cell differentiation in non-transformed cells, we tested the effect of neomorphic IDH mutants on adipocyte differentiation in vitro. Introduction of either mutant IDH or cell-permeable 2HG was associated with repression of the inducible expression of lineage-specific differentiation genes and a block to differentiation. This correlated with a significant increase in repressive histone methylation marks without observable changes in promoter DNA methylation. Gliomas were found to have elevated levels of similar histone repressive marks. Stable transfection of a 2HG-producing mutant IDH into immortalized astrocytes resulted in progressive accumulation of histone methylation. Of the marks examined, increased H3K9 methylation reproducibly preceded a rise in DNA methylation as cells were passaged in culture. Furthermore, we found that the 2HG-inhibitable H3K9 demethylase KDM4C was induced during adipocyte differentiation, and that RNA-interference suppression of KDM4C was sufficient to block differentiation. Together these data demonstrate that 2HG can inhibit histone demethylation and that inhibition of histone demethylation can be sufficient to block the differentiation of non-transformed cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, it is plausible that increased levels of 2-HG may enable a switch to an entirely HIF-independent mechanism.”
From HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells (2021) · cites this paper as [154]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [6]
In the citing paper
“In addition to its epigenetic effects, D-2HG inhibits enzymes from the canonical metabolic network (104). Such enzymes include transaminases that produce glutamate for glutathione biosynthesis, rendering IDH-mutant gliomas susceptible to treatments that deplete glutamate and enhance oxidative stress (105).”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [104]
In the citing paper
“The role of R-2-HG as an oncometabolite has been implicated in epigenetic modifications through the inhibition of α-KG-dependent dioxygenases and demethylases”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [118]
In the citing paper
“a neomorphic mutation in IDH1 and/or IDH2 causes a change in enzymatic activity and the accumulation of 2-hydroxyglutarate (2-HG), which inhibits the function of αKG-dependent enzymes such as TET2, resulting in the loss of 5hmC, an increase in DNA methylation and ultimately altered gene expression programmes that drive cancer development66.”
From Targeting cancer vulnerabilities with high-dose vitamin C (2019) · cites this paper as [66]
In the citing paper
“By blocking the enzymatic activity of histone and DNA demethylases, d-2HG can function to lock cells in a hypermethylated state that blocks differentiation and reinforces a malignant and stem cell–like phenotype (30, 172, 173, 174).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [173]
In the citing paper
“In the cancer setting, 2-HG has been shown to influence a number of biological processes, including cell differentiation, DNA methylation, and histone methylation (79–82), leading to its classification as an oncometabolite.”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [80]
In the citing paper
“For example, 2-HG acts as a competitive inhibitor of α-KG, and its production by mutant IDH1 consumes α-KG (81, 99), leading to reduced TET2 and JmjC activity in tumor cells (79, 80).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [80]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
A bivalent chromatin structure marks key developmental genes in embryonic stem cells
Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citationXu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
The complex language of chromatin regulation during transcription
Berger, S. L. (2007) · Nature · doi:10.1038/nature05915 · Cited by 2,768
Self-citationFigueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Self-citationIdentification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
ATP-citrate lyase links cellular metabolism to histone acetylation
Wellen, K. E., Hatzivassiliou, G., Sachdeva, U. M., Bui, T. V., Cross, J. R., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1164097 · Cited by 2,298
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 1,001
The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer
Liu, Y., Xu, W., Li, M., Yang, Y., Sun, D., Chen, L., Li, H., & Chen, L. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.12.019 · Cited by 37
Zhang, G., Yang, P., Guo, P.-D., Miele, L., Sarkar, F. H., Wang, Z. P., & Zhou, Q. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.03.001 · Cited by 34
Predictive biomarkers in adult gliomas
Thomas, L., Stefano, A. L. D., & Ducray, F. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000002 · Cited by 34
Oncometabolic Nuclear Reprogramming of Cancer Stemness
Menéndez, J. A., Corominas-Faja, B., Cuyàs, E., García, M. G., Fernández‐Arroyo, S., Fernández, A. F., Joven, J., Fraga, M. F., & Alarcón, T. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.12.012 · Cited by 34
Xie, D., Ren, Z., Fan, J., & Gao, Q. (2016) · PubMed Central · Cited by 34
Miyata, S., Tominaga, K., Sakashita, E., Urabe, M., Onuki, Y., Gomi, A., Yamaguchi, T., Mieno, M., Mizukami, H., Kume, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-46217-5 · Cited by 33
Kang, H. S., Lee, J. H., Oh, K., Lee, E., Han, B., Park, K.-Y., Suh, J. M., Min, J., Chi, S., Lee, S. C., et al. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154173 · Cited by 33
Take Advantage of Glutamine Anaplerosis, the Kernel of the Metabolic Rewiring in Malignant Gliomas
Martins, F., Gonçalves, L. G., Pojo, M., & Serpa, J. (2020) · Biomolecules · doi:10.3390/biom10101370 · Cited by 35
Ke, X. X., Zhang, R., Zhong, X. Z., Zhang, L., & Cui, H. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.593964 · Cited by 34
Olutasidenib: from bench to bedside
Venugopal, S., & Watts, J. M. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023009854 · Cited by 34
Mechanisms of Epigenetic Regulation of Leukemia Onset and Progression
Ntziachristos, P., Mullenders, J., Trimarchi, T., & Aifantis, I. (2013) · Advances in immunology · doi:10.1016/b978-0-12-410524-9.00001-3 · Cited by 37
Wang, P., Lv, C., & Zhu, G. (2015) · Scientific Reports · doi:10.1038/srep09150 · Cited by 35
Current and Investigational Drug Strategies for Glioblastoma
Ajaz, M., Jefferies, S., Brazil, L., Watts, C., & Chalmers, A. J. (2014) · Clinical Oncology · doi:10.1016/j.clon.2014.03.012 · Cited by 35
Mizumoto, A., Ohashi, S., Kamada, M., Saito, T., Nakai, Y., Baba, K., Hirohashi, K., Mitani, Y., Kikuchi, O., Matsubara, J., et al. (2019) · Journal of Gastroenterology · doi:10.1007/s00535-019-01549-x · Cited by 34
Molecular profiling of gliomas: potential therapeutic implications
Alentorn, A., Durán-Peña, A., Pingle, S. C., Piccioni, D. E., Idbaïh, A., & Kesari, S. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1062368 · Cited by 33
The metabolomic signature of hematologic malignancies
Allegra, A., Innao, V., Gerace, D. G., Bianco, O., & Musolino, C. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.08.002 · Cited by 32
Neomorphic mutations create therapeutic challenges in cancer
Takiar, V., Ip, C. K. M., Gao, M., Mills, G. B., & Cheung, L. W. T. (2016) · Oncogene · doi:10.1038/onc.2016.312 · Cited by 33
Macklin, P. S., Yamamoto, A., Browning, L., Hofer, M., Adam, J., & Pugh, C. W. (2020) · The Journal of Pathology · doi:10.1002/path.5402 · Cited by 33
Interpreting new molecular genetics in myelodysplastic syndromes
Abdel-Wahab, O. I., & Figueroa, M. E. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.56.3798194 · Cited by 33
Self-citationLiu, A. C. H., Cathelin, S., Yang, Y., Dai, D. L., Ayyathan, D. M., Hosseini, M., Minden, M. D., Tierens, A. M., & Chan, S. M. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1293 · Cited by 33
Deregulated proliferation and differentiation in brain tumors
Swartling, F. J., Čančer, M., Frantz, A., Weishaupt, H., & Persson, A. I. (2014) · Cell and Tissue Research · doi:10.1007/s00441-014-2046-y · Cited by 32
Popov, S., Jury, A., Laxton, R. C., Doey, L. J., Kandasamy, N., Al‐Sarraj, S., Jürgensmeier, J. M., & Jones, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056328 · Cited by 33
Pediatric high-grade astrocytomas: a distinct neuro-oncological paradigm
Gerges, N., Fontebasso, A. M., Albrecht, S., Faury, D., & Jabado, N. (2013) · Genome Medicine · doi:10.1186/gm470 · Cited by 33
Jiang, B., Zhang, J., Xia, J., Zhao, W., Wu, Y., Shi, M., Luo, L., Zhou, H., Chen, A., Ma, H., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.053 · Cited by 33
Li, A. M., & Ye, J. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-062822-120857 · Cited by 31
Oxygen Concentration Controls Epigenetic Effects in Models of Familial Paraganglioma
Her, Y. F., Nelson-Holte, M. H., & Maher, L. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127471 · Cited by 34
NADP+-dependent IDH1R132 mutation and its relevance for glioma patient survival
Tewarie, N. M. S. B., Burgers, I. A. V., Dawood, Y., den Boon, H. C., den Brok, M. G. H. E., Klunder, J. H., Koopmans, K. B., Rademaker, E., van den Broek, H. B., van den Bersselaar, S. M., et al. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2013.02.022 · Cited by 33
Aslanyan, M. G., Kroeze, L. I., Langemeijer, S. M. C., Koorenhof‐Scheele, T. N., Massop, M., van Hoogen, P., Stevens-Linders, E., van de Locht, L. T., Tönnissen, E., van der Heijden, A., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2055-7 · Cited by 34
Neves, R. P. P., Fernandes, P. A., & Ramos, M. J. (2015) · ACS Catalysis · doi:10.1021/acscatal.5b01928 · Cited by 32
Upadhyay, V. A., Brunner, A. M., & Fathi, A. T. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.003 · Cited by 33
Exogenous Gene Transmission of Isocitrate Dehydrogenase 2 Mimics Ischemic Preconditioning Protection
Kolb, A. L., Corridon, P. R., Zhang, S., Xu, W., Witzmann, F. A., Collett, J. A., Rhodes, G. J., Winfree, S., Bready, D., Pfeffenberger, Z. J., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017060675 · Cited by 32
Pediatric hemispheric high-grade glioma: targeting the future
Coleman, C., Stoller, S., Grotzer, M. A., Stücklin, A. G., Nazarian, J., & Mueller, S. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09850-5 · Cited by 35
Challenges and Perspectives of Standard Therapy and Drug Development in High-Grade Gliomas
Chelliah, S. S., Paul, E. A. L., Kamarudin, M. N. A., & Parhar, I. S. (2021) · Molecules · doi:10.3390/molecules26041169 · Cited by 32
The Role of Ten-Eleven Translocation Proteins in Inflammation
Gerecke, C., Rodrigues, C. E., Homann, T., & Kleuser, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.861351 · Cited by 36
Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
Cho, S. M., Esmail, A., Raza, A., Dacha, S., & Abdelrahim, M. (2022) · Cancers · doi:10.3390/cancers14112641 · Cited by 32
The multi-omic landscape of transcription factor inactivation in cancer
Teschendorff, A. E., Zheng, S., Feber, A., Yang, Z., Beck, S., & Widschwendter, M. (2016) · Genome Medicine · doi:10.1186/s13073-016-0342-8 · Cited by 30
Radiomics, Metabolic, and Molecular MRI for Brain Tumors
Kickingereder, P., & Andronesi, O. C. (2018) · Seminars in Neurology · doi:10.1055/s-0037-1618600 · Cited by 31
Andrējeva, D., Kugler, J., Nguyen, T., Malmendal, A., Holm, M. L., Toft, B. G., Loya, A. C., & Cohen, S. M. (2018) · BMC Cancer · doi:10.1186/s12885-018-5061-7 · Cited by 30
Hypoxic adaptation of mitochondria and its impact on tumor cell function
Benej, M., Papandreou, I., & Denko, N. C. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.03.004 · Cited by 33
Ferroptosis: iron release mechanisms in the bioenergetic process
Lee, J., & Roh, J. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10252-8 · Cited by 34
Untuning the tumor metabolic machine: HIF-α: pro- and antitumorigenic?
Young, R. M., & Simon, M. C. (2012) · Nature Medicine · doi:10.1038/nm.2865 · Cited by 31
Koszarska, M., Bors, A., Feczko, A., Meggyesi, N., Bátai, Á., Csomor, J., Ádám, E., Kozma, A., Orbán, T. I., Lovas, N., et al. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.736981 · Cited by 32
Metabolism – A cornerstone of cancer initiation, progression, immune evasion and treatment response
Lunt, S. Y., & Fendt, S. (2017) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2017.12.006 · Cited by 30
Clinical and immunological correlates of long term survival in glioblastoma
Czapski, B., Baluszek, S., Herold‐Mende, C. C., & Kaminska, B. (2018) · Współczesna Onkologia · doi:10.5114/wo.2018.73893 · Cited by 31
Pheochromocytomas and Paragangliomas: Bypassing Cellular Respiration
Cascón, A., Remacha, L., Calsina, B., & Robledo, M. (2019) · Cancers · doi:10.3390/cancers11050683 · Cited by 33
Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas
Park, J., & Turcan, Ş. (2019) · Cancers · doi:10.3390/cancers11101616 · Cited by 33
Fujiwara, H., Tateishi, K., Misumi, K., Hayashi, A., Igarashi, K., Kato, H., Nakatsuka, T., Suzuki, N., Yamamoto, K., Kudo, Y., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-55211-w · Cited by 32
Treating acute myeloid leukemia in the modern era: A primer
Blum, W. G., & Mims, A. S. (2020) · Cancer · doi:10.1002/cncr.32904 · Cited by 31
Crispo, F., Pietrafesa, M., Condelli, V., Maddalena, F., Bruno, G., Piscazzi, A., Sgambato, A., Esposito, F., & Landriscina, M. (2020) · Molecules · doi:10.3390/molecules25163754 · Cited by 32
Role of succinate dehydrogenase deficiency and oncometabolites in gastrointestinal stromal tumors
Zhao, Y., Feng, F., Guo, Q., Wang, Y., & Zhao, R. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i34.5074 · Cited by 35
Rohde, J. M., Surendra, K., Pragani, R., Liu, L., Fang, Y., Zhang, W., McIver, A. L., Zheng, H., Liu, Q., Davis, M. I., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00019 · Cited by 31
H3K4 Methylation in Aging and Metabolism
Hsu, C.-L., Lo, Y., & Kao, C.-F. (2021) · Epigenomes · doi:10.3390/epigenomes5020014 · Cited by 31
From the (Epi)Genome to Metabolism and Vice Versa; Examples from Hematologic Malignancy
Karagianni, P., Giannouli, S., & Voulgarelis, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126321 · Cited by 35
Nunn, E. R., Shinde, A. B., & Zaganjor, E. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.821278 · Cited by 33
Franson, A. T., McClellan, B. L., Varela, M. L., Comba, A., Syed, M. F., Banerjee, K., Zhu, Z., González, N., Candolfi, M., Lowenstein, P. R., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.966458 · Cited by 31
Low-grade and anaplastic oligodendroglioma
van den Bent, M. J., Bromberg, J. E. C., & Buckner, J. C. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802997-8.00022-0 · Cited by 32
Decrotonylation of AKT1 promotes AKT1 phosphorylation and activation during myogenic differentiation
Qian, Z., Ye, J., Li, J., Che, Y., Yu, W., Xu, P., Lin, J., Ye, F., Xu, X., Su, Z., et al. (2022) · Journal of Advanced Research · doi:10.1016/j.jare.2022.10.005 · Cited by 30
Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future Perspectives
Carosi, F., Broseghini, E., Fabbri, L., Corradi, G., Gili, R., Forte, V., Roncarati, R., Filippini, D. M., & Ferracin, M. (2024) · Cancers · doi:10.3390/cancers16152752 · Cited by 31
Polívka, J., Polívka, J., Rohan, V., Pešta, M., Repik, T., Pitule, P., & Topolčan, O. (2014) · BioMed Research International · doi:10.1155/2014/735659 · Cited by 31
Glioblastoma management in the temozolomide era: have we improved outcome?
Lwin, Z., MacFadden, D. R., Alzahrani, A., Atenafu, E. G., Miller, B. A., Sahgal, A., Ménard, C. M., Laperrière, N., & Mason, W. P. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1230-3 · Cited by 30
Santini, V., Melnick, A. M., Maciejewski, J. P., Duprez, E., Nervi, C., Cocco, L., Ford, K. G., & Mufti, G. J. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.06.004 · Cited by 30
Self-citationSuccessive distinct high‐grade gliomas in L‐2‐hydroxyglutaric aciduria
Patay, Z. J., Orr, B. A., Shulkin, B. L., Hwang, S. N., Yuan, Y., Broniscer, A., Boop, F. A., & Ellison, D. W. (2014) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-014-9782-8 · Cited by 29
Huse, J. T., Wallace, M., Aldape, K., Berger, M. S., Bettegowda, C., Brat, D. J., Cahill, D. P., Cloughesy, T. F., Haas-Kogan, D. A., Marra, M. A., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not229 · Cited by 31
Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?
Bewersdorf, J. P., Stahl, M. F., & Zeidan, A. M. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1546854 · Cited by 30
Aberrant mitochondrial function in ageing and cancer
Whitehall, J. C., & Greaves, L. C. (2019) · Biogerontology · doi:10.1007/s10522-019-09853-y · Cited by 34
Extraordinary Cancer Epigenomics: Thinking Outside the Classical Coding and Promoter Box
Murtha, M. J., & Esteller, M. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.08.004 · Cited by 30
The Power Behind the Throne: Senescence and the Hallmarks of Cancer
Hoare, M., & Narita, M. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050352 · Cited by 33
Glioma and post-translational modifications: A complex relationship
Pienkowski, T., Kowalczyk, T., Cysewski, D., Kretowski, A. J., & Ciborowski, M. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189009 · Cited by 30
Onciul, R., Brehar, F.-M., Toader, C., Covache-Busuioc, R.-A., Glavan, L.-A., Bratu, B.-G., Costin, H. P., Dumitrascu, D.-I., Șerban, M., & Ciurea, A. V. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46030153 · Cited by 30
Bravo, G. M., Lee, E., Merchán, B., Kantarjian, H. M., & Garcia‐Manero, G. (2014) · British Journal of Haematology · doi:10.1111/bjh.12957 · Cited by 32
Contemporary murine models in preclinical astrocytoma drug development
McNeill, R. S., Vitucci, M., Wu, J., & Miller, C. R. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou288 · Cited by 31
Enigmas of IDH mutations in hematology/oncology
Heuser, M., Cruz, M. M. A., Goparaju, R., & Chaturvedi, A. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.005 · Cited by 28
Purkait, S., Sharma, V., Kumar, A., Pathak, P., Mallick, S., Jha, P., Sharma, M. C., Suri, V. S., Julka, P. K., Suri, A., et al. (2016) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2016.02.002 · Cited by 29
Further understanding of the pathology of glioma: implications for the clinic
Camelo-Piragua, S. I., & Kesari, S. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1194755 · Cited by 29
IDH1 Arg-132 mutant promotes tumor formation through down-regulating p53
Jiang, B., Zhao, W., Shi, M., Zhang, J., Chen, A., Ma, H., Suleman, M., Lin, F., Zhou, L., Wang, J., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.001385 · Cited by 29
Yang, R., Zhao, Y., Gu, Y., Yang, Y., Gao, X., Yuan, Y., Xiao, L., Zhang, J., Sun, C., Yang, H. K., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01439-0 · Cited by 29
T herapeutic targeting of chromatin: status and opportunities
Siklos, M. I., & Kubicek, S. (2021) · FEBS Journal · doi:10.1111/febs.15966 · Cited by 28
Polycomb repressive complex 2 in the driver’s seat of childhood and young adult brain tumours
Krug, B., Harutyunyan, A. S., Deshmukh, S., & Jabado, N. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.05.006 · Cited by 29
Tupe-Waghmare, P., Malpure, P., Kotecha, K. V., Beniwal, M., Santosh, V., Saini, J. S., & Ingalhalikar, M. (2021) · IEEE Access · doi:10.1109/access.2021.3136293 · Cited by 29
RIF1-ASF1-mediated high-order chromatin structure safeguards genome integrity
Feng, S., Ma, S., Li, K., Gao, S., Ning, S., Shang, J., Guo, R., Chen, Y., Blumenfeld, B., Simon, I., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28588-y · Cited by 29
Pardhi, E. R., Yadav, R., Chaurasiya, A., Madan, J., Guru, S. K., Singh, S. B., & Mehra, N. K. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121771 · Cited by 29
Brooks, E. E., Wu, X., Hanel, A., Nguyen, S., Wang, J., Zhang, J. H., Harrison, A., & Zhang, W. (2014) · SLAS DISCOVERY · doi:10.1177/1087057114541148 · Cited by 29
Shannar, A., Sarwar, M. S., & Kong, A. T. (2022) · Preventive Nutrition and Food Science · doi:10.3746/pnf.2022.27.4.335 · Cited by 29
de Cedrón, M. G., Palomares, R. M., & de Molina, A. R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1169168 · Cited by 34
Venetoclax in adult acute myeloid leukemia
Hu, M., Li, W., Zhang, Y., Liang, C., Tan, J. E., & Wang, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115820 · Cited by 29
Richardson, T. E., Walker, J. M., Hambardzumyan, D., Brem, S. S., Hatanpaa, K. J., Viapiano, M. S., Pai, B., Umphlett, M., Becher, O. J., Snuderl, M., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02761-7 · Cited by 28
Common Driver Mutations in AML: Biological Impact, Clinical Considerations, and Treatment Strategies
Nong, T., Mehra, S., & Taylor, J. (2024) · Cells · doi:10.3390/cells13161392 · Cited by 32
Bridging epigenomics and tumor immunometabolism: molecular mechanisms and therapeutic implications
Xie, X., Liu, W. L., Yuan, Z., Chen, H.-Q., & Mao, W. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02269-y · Cited by 30
Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia
Sirenko, M., Lee, S., Sun, Z., Chaligne, R., Loghavi, S., Asimomitis, G., Brierley, C. K., Bernard, E., Cai, S. F., Myers, R. M., et al. (2025) · Cell Stem Cell · doi:10.1016/j.stem.2025.04.012 · Cited by 28
Self-citationAlentorn, A., Sanson, M., & Idbaïh, A. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328357f4ea · Cited by 28
Associations among Metabolism, Circadian Rhythm and Age-Associated Diseases
Cao, Y., & Wang, R.-H. (2017) · Aging and Disease · doi:10.14336/ad.2016.1101 · Cited by 28
Epigenomics-Guided Drug Development: Recent Advances in Solving the Cancer Treatment “jigsaw puzzle”
Dzobo, K. (2019) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2018.0206 · Cited by 29
Aguado-Fraile, E., Tassinari, A. M., Ishii, Y., Sigel, C., Lowery, M. A., Goyal, L., Gliser, C., Jiang, L., Pandya, S. S., Wu, B., et al. (2021) · Future Oncology · doi:10.2217/fon-2020-1274 · Cited by 28
Wang, Z., Zhang, Z., Li, Y., Sun, L., Peng, D., Du, D., Zhang, X., Han, L., Zhao, L., Lu, L., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.005 · Cited by 28
Long non-coding RNA in glioma: novel genetic players in temozolomide resistance
Roh, J., Im, M., Kang, J., Youn, B., & Kim, W. (2023) · Animal Cells and Systems · doi:10.1080/19768354.2023.2175497 · Cited by 28
Low-Grade Gliomas: Histological Subtypes, Molecular Mechanisms, and Treatment Strategies
Toader, C., Eva, L., Costea, D., Corlatescu, A.-D., Covache-Busuioc, R.-A., Bratu, B.-G., Glavan, L.-A., Costin, H. P., Popa, A. A., & Ciurea, A. V. (2023) · Brain Sciences · doi:10.3390/brainsci13121700 · Cited by 31
Law, J. M., Stark, S., Liu, K., Liang, N. E., Hussain, M. M., Leiendecker, M., Ito, D., Verho, O., Stern, A. M., Johnston, S. E., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00264 · Cited by 28
Metabolic Regulation of the Epitranscriptome
Thomas, J. M., Batista, P. J., & Meier, J. L. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.8b00951 · Cited by 30
Epigenetic Reprogramming and Emerging Epigenetic Therapies in CML
Bugler, J., Kinstrie, R., Scott, M. T., & Vetrie, D. L. P. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00136 · Cited by 28
Translational genomics of sinonasal cancers
Hermsen, M. A. J. A., Riobello, C., García‐Marín, R., Cabal, V. N., Suárez–Fernández, L., López, F., & Llorente, J. L. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.016 · Cited by 27
Metadata
- Authors
- Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., Figueroa, M. E., Melnick, A., Wellen, K. E., O’Rourke, D. M., Berger, S. L., Chan, T. A., Levine, R. L., Mellinghoff, I. K., & Thompson, C. B.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- University of Pennsylvania (US)
- Weill Cornell Medicine (US)
- Corresponding author
- Thompson, Craig B.
- ORCID
- Venue
- Nature
- Published
- 2012-02-15
- Volume
- 483
- Issue
- 7390
- Pages
- 474-478
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3478770
- OpenAlex
- W2154313451
- Cited by
- 1,985
- References
- 30
- Citations by year
- 2026: 81 · 2025: 93 · 2024: 106 · 2023: 125 · 2022: 122 · 2021: 180 · 2020: 170 · 2019: 153 · 2018: 146 · 2017: 163 · 2016: 151 · 2015: 123 · 2014: 138 · 2013: 136 · 2012: 91
- FWCI
- 74.69
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- University of Pennsylvania
- National Cancer Institute (R01CA078831, R01CA105463, U54CA143798)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- 2-hydroxyglutarate, histone demethylation, histone methylation, glioma, oncometabolites, DNA hypermethylation, hypoxia-inducible factor, adipogenesis, neural progenitor cells
- MeSH terms
- Animals, Astrocytes, Cell Differentiation, Enzyme Induction, Gene Expression Regulation, Glioma, Glutarates, Histones, Humans, Isocitrate Dehydrogenase, Methylation, Mutation, Promoter Regions, Genetic, Adipocytes, Cell Lineage, DNA Methylation, 3T3-L1 Cells, Cell Line, Tumor, Mice, Jumonji Domain-Containing Histone Demethylases, HEK293 Cells, Neural Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
